Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Non Operating Income (2019 - 2026)

InMed Pharmaceuticals has reported Other Non Operating Income over the past 5 years, most recently at $18136.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 137.98% year-over-year to $18136.0; the TTM value through Dec 2025 reached -$38886.0, up 61.8%, while the annual FY2025 figure was -$28471.0, 54.02% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $18136.0 at InMed Pharmaceuticals, up from -$56994.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $59896.0 in Q4 2023 and troughed at -$96791.0 in Q3 2022.
  • A 5-year average of -$16387.6 and a median of -$12449.0 in 2023 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: soared 573.0% in 2022 and later crashed 1662.02% in 2024.
  • Year by year, Other Non Operating Income stood at $3007.0 in 2021, then soared by 573.0% to $20237.0 in 2022, then skyrocketed by 195.97% to $59896.0 in 2023, then plummeted by 179.73% to -$47753.0 in 2024, then skyrocketed by 137.98% to $18136.0 in 2025.
  • Business Quant data shows Other Non Operating Income for INM at $18136.0 in Q4 2025, -$56994.0 in Q3 2025, and $22137.0 in Q2 2025.